ß2-Glycoprotein I Screen ELISA

产品名称：ß2-Glycoprotein I Screen ELISA
产    地：Demeditec 
产品货号：DE7270
产品规格：96 Tests
产品说明：
Special remarks:
Anti-b2-Glycoprotein I Screen is an indirect solid phase enzyme immunoassay (ELISA) for the semiquantitative screening of IgG, IgM and IgA class autoantibodies against b2-Glycoprotein I in human serum or plasma. The assay is intended for in vitro diagnostic use only as an aid in the diagnosis of an increased risk of thrombosis in patients with Systemic Lupus Erythematosus (SLE) or lupus-like disorders.
Anti-b2-Glycoprotein I antibodies are associated with the diseases of the antiphospholipid syndrome, like thrombosis, thrombocytopenia or fetal loss in the context of systemic lupus erythematosus. b2-Glycoprotein I (apolipoprotein H) is a 50 kDa b2-globulin occurring in plasma at a level of 200 µg/ml. It has been found that b2-Glycoprotein I (b2GPI) inhibits the intrinsic coagulation pathway and, therefore, it is involved in the regulation of blood coagulation. b2GPI is associated in vivo with negatively-charged substances, e.g. anionic phospholipids, heparin and lipoproteins. The phospholipid binding region is located on its fifth domain. Recently, b2-Glycoprotein I has become well-known as a co-factor for anti-Cardiolipin auto-antibodies. Several studies confirmed its indispensable role in proper binding of anti-Cardiolipin antibodies to immobilized Cardiolipin. Detailed investigations about the nature of the Cardiolipin-b2GPI-complex have shown that epitopes on the fifth domain of b2GPI are the real target of "anti-Cardiolipin antibodies" - even in the absence of negatively-charged phospholipids. b2GPI is not only a prerequisite for the binding of anti-Cardiolipin antibodies; it has now been identified as the primary antigen for these antibodies. Samples from clinical patients with the antiphospholipid syndrome were tested for anti-Cardiolipin and anti-b2GPI antibodies. Good correlations between the anti-Cardiolipin and anti-b2GPI values confirm the statement above. Autoantibodies against b2-Glycoprotein I are described for various autoimmune diseases. The presence of anti-b2GPI antibodies can be related to the development of arterial and venous thromboses, venous thromboembolism, thrombocytopenia and fetal loss.
Anti-b2-Glycoprotein I antibodies are found in the immunoglobulin classes IgG, IgM and IgA. The determination of IgM antibodies is a valuable indicator in the diagnosis of beginning autoimmune diseases, whereas IgG antibodies will be found in progressive stages of mani-fested autoimmune disorders. Anti-b2GPI IgG antibody titers correlate well with the clinical status of the patients in thrombosis, thromboembolism and repeated fetal loss, while anti-b2GPI IgM antibodies show a significant association with thrombosis and thrombocytopenia.
Indications for determination of anti-b2-Glycoprotein I antibodies:
- SLE 
- arterial and venous thromboses     
- venous thromboembolism  
- thrombocytopenia  
- fetal loss
上海玉博生物技术有限公司在为生命科学领域提供丰富的产品与信息资源方面处于国内**地位，公司提供的产品涵盖了二十多个国家近五十万种产品，而且产品的数量与信息在不断的增长和更新，公司提供的产品能够使生命科学工作者加快对生物化学，分子生物学，细胞生物学以及蛋白质组学研究的认知，以及分子诊断和临床医学领域的应用。

产品留言

标题

联系人

联系电话

内容

验证码

点击换一张

注：1.可以使用快捷键Alt+S或Ctrl+Enter发送信息!
2.如有必要,请您留下您的详细联系方式!